Safety and Efficacy Study Evaluating Dimebon in Patients With Mild to Moderate Alzheimer's Disease on Donepezil

• Status: Completed
• Trial end date: 2011-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine if Dimebon is safe and effective in patients with mild to moderate Alzheimer's disease on Donepezil.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Medivation, Inc.
• Collaborator: Pfizer
• Treatments: Donepezil

Criteria

Inclusion Criteria:

• Mild-to-moderate Alzheimer's disease (AD)

• Probable AD (Diagnostic Statistical Manual of Mental Disorders-IV-Text Revision (DSM-IV-TR))

• Mini-Mental State Examination (MMSE) score between 12 and 24, inclusive

• Stable on donepezil for at least 6 months

Exclusion Criteria:

• Other causes of dementia

• Major structural brain disease

• Unstable medical condition or significant hepatic or renal disease